#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Colorectal adenocarcinoma Mitochondrial myopathy Congenital cystic kidney disease Pleural mesothelioma Mantle cell lymphoma stage II Small cell lung cancer extensive stage Lung adenocarcinoma Non-Hodgkin's lymphoma unspecified histology indolent Progressive supranuclear palsy Angiosarcoma recurrent Diffuse large B-cell lymphoma Peritoneal mesothelioma malignant Loeys-Dietz syndrome Becker's muscular dystrophy Renal cancer metastatic More trials…

    Learn about Rare Diseases

    Leukoencephalopathy – Diagnostics Primary hyperoxaluria Retinitis pigmentosa – Treatment Haemophilia A without inhibitors – Basic Information Hereditary neuropathic amyloidosis – Basic Information Haemophilia A with anti factor VIII – Trials in Disease Angiosarcoma non-metastatic – Basic Information Hepatic angiosarcoma Lymphangiosarcoma – Basic Information IgA nephropathy – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    PEGZILARGINASE Dexpanthenol Other Immunosuppressants Rmc-035 Vibosameran Sodium Lactate Solution Chlorphenamine SIGVOTATUG VEDOTIN Abc-15Bo-116 Thalidomide Tolinapant Lactate Atomoxetine Tamoxifen DICLOFENAC POTASSIUM Insulin Human (Rdna) Padeliporfin Ioflupane (123I) ULIXERTINIB VISUGROMAB Avalotcagene Ontaparvovec More therapies…

    Learn about Your Condition

    Rectal cancer stage II Bronchopulmonary aspergillosis Bladder cancer stage II Radicular pain Bile duct adenocarcinoma Sarcoma Chronic spontaneous urticaria B-cell lymphoma recurrent Angina pectoris Transplantation complication Diabetic gastroparesis Pleomorphic leiomyosarcoma Small intestine leiomyosarcoma Cardiac valve disease Breast cancer female More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2oq Bnmcanuuo Da Sevfnj Mckxadryhjr Bs 1lbk Mvfihjqknu 1dspsq Frzedh

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Oral Azacitidine for Patients with Low or Intermediate-Risk Myelodysplastic Syndrome

    Not recruiting

    4 1
    Investigated Drugs:
    • Azacitidine
    Austria Czechia Denmark France Germany Greece +4

  • Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • LUXDEGALUTAMIDE
    • Abiraterone
    • Degarelix
    Czechia France Germany Italy The Netherlands Poland +1

  • Study of RMC-6236 compared to standard therapy in previously treated metastatic pancreatic ductal adenocarcinoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Fluorouracil
    • Folinic Acid
    France Germany Italy Spain

  • Study of ICT01 and Pembrolizumab for Patients with Advanced-Stage, Relapsed/Refractory Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Haematological malignancy
    • Neoplasm malignant
    Investigated Drugs:
    • Ict01
    • Pembrolizumab
    Belgium France Germany Spain

  • Study of Tazemetostat with R-CHOP for Newly Diagnosed Diffuse Large B Cell Lymphoma or High-Risk Follicular Lymphoma Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Vincristine
    • Doxorubicin
    • Cyclophosphamide
    Belgium France

  • Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Cetrelimab
    • Gemcitabine Hydrochloride
    Belgium France Germany Greece Italy The Netherlands +2

  • Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Raludotatug Deruxtecan
    • Doxorubicin Hydrochloride, Liposomal
    • Paclitaxel
    Czechia Finland France Germany Greece Italy +3

  • Study on Ruxolitinib and Drug Combination for Critically Ill Adults with Acquired Hemophagocytic Syndrome

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Etoposide
    • Lidocaine Hydrochloride Monohydrate
    France
Previous Page
1 … 40 41 42

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!